• Clinical and Experimental Reproductive Medicine
• /
• 제21권3호
• /
• pp.241-245
• /
• 1994

Despite increasing success rate of IVF, poor response to ovarian stimulation remains a problem. So, attempts to improve ovarian responses, for example, by using combined gonadotropin-releasing hormone analogue(GnRH-a) and human menopausal gonadotropin(hMG) have shown limited success. It is reported that response of granulosa cells in vitro to FSH is stimulated by co-incubation with IGF-l, and IGF-l production can be increased by growth hormone. This suggest that combination regimen of G.H. and hMG may augment follicle recruitment. In fifteen patients who had previous history of poor ovarian response to gonadotropin stimulation after pituitary suppression with mid -luteal GnRH-a, the effectiveness of cotreatment with G.H. in IVF program was evaluated using a combination regimen of G.R. and hMG at Korea University Hospital IVF Clinic. Ovarian responses to gonadotropin stimulation in control and GH-treated cycles assessed by total dose and duration of hMG treatment, follicular development and peak $E_2$ level, number of eggs retrieved, and fertilization rates were also assessed. In each group, serum and follicular fluid IGF-1 concentrations on day of egg collection were measured by RIA after acidification and extraction by reveresed phase chromatography. Patients receiving G.H. required fewer days and ampules of gonadotropins, developed more oocytes, and more embryos transferred. But, the differences were not statistically significant, except the duration of hMG treatment. Our data showed a significantly higher concentration of IGF-l in the serum, not in the follicular fluid, of patients treated with G.H. compared with control group. These data suggest that growth hormone treatment does not improve the ovarian response in women with limited ovarian reserve to gonadotropin stimulation for IVF.

• Preventive Nutrition and Food Science
• /
• 제16권2호
• /
• pp.110-116
• /
• 2011

This study examined the growth effects of yeast hydrolysate (YH) and a traditional Korean herbal mixture (HM, a mixture of safflower seed and gasiogapi extract). Three-week old male SD rats were divided into the following five groups: negative control (saline), positive control (foremilk 0.5 g/kg/day), YH (YH 0.5 g/kg/day), HM (HM 0.2 g/kg/day), and YH+HM (YH 0.5 g/kg/day and HM 0.2 g/kg/day). Tibia bone length was 9.22 mm in the normal control rats, while both the YH and YH+HM groups had significantly longer tibia bones than the control rats (9.75 mm and 10.46 mm, respectively). The proximal epiphyses of YH, HM, and YH+HM measured 0.75, 0.70, and 0.75 mm, respectively, while the length in the control group was 0.50 mm. Plasma insulin growth factor-1 (IGF-1) level was slightly higher in the YH group (1.36 mg/mL) than in the control rats (1.29 mg/mL), but the difference was not significant. Plasma IGF-1 level was significantly increased in the HM (1.49 mg/mL) and YH+HM (1.53 mg/mL) groups compared to the control group (1.29 mg/mL). Growth hormone (GH) levels in YH (17.45 ng/mL), HM (15.49 ng/mL), and YH+HM (16.07 ng/mL) were significantly different compared to the control group (3.63 ng/mL).

• Clinical and Experimental Pediatrics
• /
• 제52권12호
• /
• pp.1370-1376
• /
• 2009

목 적:성선자극호르몬 효능약제로 성조숙증을 치료하는 동안에 성선자극호르몬이 억제되고 성선 스테로이드가 감소되면 사춘기 발달동안의 골량에 좋지 않은 영향을 미칠 수가 있어, 성조숙증 혹은 조기 성성숙이 있는 여아에서 성선자극호르몬 효능약제 단독 혹은 성장호르몬과 같이 사용하여 치료하는 경우에 단기간 동안의 골밀도의 변화가 어떠한지를 알아보고자 하였다. 방 법:성장클리닉을 방문한 여아들 중 특발성 성조숙증 혹은 조기 성성숙을 보이며 역연령에 비하여 골연령이 증가되어 있는 여아 40명(역연령 $9.0{\pm}1.5$세, 골연령 $11.6{\pm}1.3$년)을 대상으로, 26명은 성선자극호르몬 효능약제 단독으로 치료하였고(Group I), 14명은 성장호르몬과 병합요법(Group II)으로 치료하였다. 치료 전후에 골연령과 골밀도를 구하고, 역연령과 골연령에 대한 골밀도를 비교하였다. 결 과:전체 환아에서 치료 전후에 역연령으로 비교한 골밀도는 정상범위에 있었으나, 골연령으로 비교해 보면 정상범위에 비하여 감소되어 있었다(P<0.05). 치료기간 동안의 골밀도의 표준편차점수는 역연령 기준으로는 변화가 없었으나, 골연령 기준으로는 의미 있는 증가를 보였다(P<0.05). 치료 전후에 성선자극호르몬 효능약제 단독 치료군의 골밀도 표준편차점수는 역연령 혹은 골연령 기준으로 변화가 없었으나, 성장호르몬 병합 치료군의 골밀도 표준편차점수는 역연령 기준에는 변화가 없었으나 골연령 기준으로는 의미 있는 증가를 보였다(P<0.05). 결 론:성선자극호르몬 방출호르몬 효능약제를 사용하는 동안 역연령에 따른 골밀도의 저하는 관찰되지 않았으나, 골연령에 따른 골밀도의 저하는 관찰되어, 투약 중단 후 성선 기능이 회복되면 골밀도의 정상화의 가능성에 대한 추적 관찰이 필요하겠다. 한편으로는 성장호르몬을 같이 치료한 경우에는 치료 경과 중 골밀도의 의미 있는 증가를 볼 수 있어 성선자극호르몬 효능약제를 사용할 때 고려해야 할 사항으로 보인다.

• 한국식품위생안전성학회:학술대회논문집
• /
• 한국식품위생안전성학회 1994년도 추계 학술 심포지움
• /
• pp.15-26
• /
• 1994

Bovine somatotropin(bST) or bovine growth hormone (bGH) is a protein of 191 amino acids produced by the anterior pituitary gland of cattle. Recombinant bovine somatotropin(rbST) is biosynthetic versions of the naturally occurring pituitary hormone in cows. The use of rbST in dairy cows promises to improve the efficiency of milk production around the world. Using recombinant DNA technology, bST can now be produced in commercial quantities. The recombinant bST(rbST) is biologically identical to the found in the bovine pituitary. Milk from rbST-treated cows has been found to have the same nutritional value and composition as milk from untreated cows. In November of 1993, rbST finally was approved by the FDA, nearly 10 years after filing a licence applica-tion. rbST has been one of the most extensively studied animal drug products to be reviewed by the agency. Three scientific facts will help to reassure the public about the safety of the milk suppy.: 1. rbST has no biological activity in humans when indigested orally or when given by intramuscular injection. 2. Insulin-like growth factor 1(IGF-1) is not orally active. Any changes in IGF-1 levels in milk are well within normal variation and are lower than those reported in human milk. 3. All cow's milk contains bST, and no significant change in bST levels in milk occurs as a result of giving cows supplemental bST. Based on the scientific evidence, the public can be confident that milk and meat from rbST-treated cows is safe to consumers.

• Journal of Genetic Medicine
• /
• 제19권1호
• /
• pp.32-37
• /
• 2022

Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive lysosomal disorder caused by the deficiency of arylsulfatase B due to mutations in the ARSB gene. Here, we report the case of a Korean female with a novel variant of MPS VI. A Korean female aged 5 years and 8 months, who is the only child of a healthy non-consanguineous Korean couple, presented at our hospital for severe short stature. She had a medical history of umbilical hernia and recurrent otitis media. Her symptoms included snoring and mouth breathing. Subtle dysmorphic features, including mild coarse face, joint contracture, hepatomegaly, and limited range of joint motion, were identified. Radiography revealed deformities, suggesting skeletal dysplasia. Growth hormone (GH) provocation tests revealed complete GH deficiency. Targeted exome sequencing revealed compound heterozygous mutations in the ARSB genes c.512G>A (p.Gly171Asp; a pathogenic variant inherited from her father) and c.1157C>T (p.Ser386Phe; a novel variant inherited from her mother in familial genetic testing). Quantitative tests revealed increased urine glycosaminoglycan (GAG) levels and decreased enzyme activity of arylsulfatase B. While on enzyme replacement therapy and GH therapy, her height increased drastically; her coarse face, joint contracture, snoring, and obstructive sleep apnea improved; urine GAG decreased; and left ventricular mass index was remarkably decreased. We report a novel variant-c.1157C>T (p.Ser386Phe)-of the ARSB gene in a patient with MPS VI; these findings will expand our knowledge of its clinical spectrum and molecular mechanisms.

• 한방재활의학과학회지
• /
• 제18권2호
• /
• pp.97-109
• /
• 2008

Objectives : Effects of Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) on intellectual development and learning ability were investigated growth and intellectual impairment rat with insufficient nutrition diet. Methods : We divided male Sprague-Dawley rats into 4 groups(A, B, C, D). They were normal group(A), growth deficiency rat with insufficient nutrition diet group(B), growth deficiency rat with 0.1% Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) group(C) and growth deficiency rat with 0.2% Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) group(D). They were administered for 5 weeks. We measured body weight, serum growth hormone, insulin-like growth factor and thyroid stimulating hormone, RBC, concentration of Hb and PCV ratio, total WBC and its composition, the values of plasma glutamic oxaloacetic transaminase(GOT) and glutamic pyruvic transaminase(GPT) activities and morris water maze test in escape distance, escape time and escape speed. Results : 1. Body weight showed a tendency to increase in the Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) groups and 0.2% Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) group showed significantly different than control groups. 2. Serum growth hormone, insulin-like growth factor and thyroid stimulating hormone showed a tendency to increase in Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) groups, however these values showed no significantly different. 3. About the counts of RBC, 0.1% and 0.2% Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) groups showed significantly different than control groups. Concentration of Hb was higher than control group in Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) groups. And 0.2% Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) group showed significantly different than control groups in PCV ratio. 4. The counts of total WBC and its composition showed no significantly different in all treatment groups. 5. The values of plasma glutamic oxaloacetic transaminase(GOT) and glutamic pyruvic transaminase(GPT) activities showed no significantly different in all treatment groups. 6. In the morris water maze test, in escape distance and escape speed, Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) groups showed no significantly different than control group. But Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) groups showed the increasing tendency. Conclusions : So Kyungohkgo($Qi{\acute{o}}ng\;y{\grave{u}}\;g{\grave{a}}o$) have an effect of promoting growth of rats and might be effect to treat various kinds of growth delay in children.

• Clinical and Experimental Pediatrics
• /
• 제52권2호
• /
• pp.227-233
• /
• 2009

목 적 : 소아청소년기 GHD 환자들은 성인기에 진단된 환자보다 체성분과 심혈관계의 변화가 심한 것으로 알려져 있어 성인기에도 GHD가 지속되면 성장호르몬 치료를 꼭 받아야 한다. 본 연구에서는 소아청소년기에 GHD로 진단 받은 성인 환자들을 대상으로 ITT를 시행하여 성인기에도 GHD가 지속되는 요인을 살펴보고, 성인기에도 GHD가 지속될 가능성이 높은 대상을 알아보고자 한다. 방 법 : 성인키에 도달한 55명(남 39명, 여 16명)을 대상으로 ITT의 최대 성장호르몬 값이 $3{\mu}g/L$ 미만이면 성인기 GHD로 진단하였다. 특발성 GHD 환자(n=12)는 뇌하수체 구조적인 이상이 있는 2명과 둔위 분만 또는 가사의 병력이 있는 10명이었으며, 기질성 GHD 환자(n=43)는 시상하부-뇌하수체를 침범하는 뇌종양(n=33), 그 외의 뇌종양(n=3), 뇌수막염(n=3), 백혈병(n= 2), 지주막낭종(n=1), 뇌하수체염(n=1)에 해당하였다. 결 과 : 성인기에도 GHD가 지속된 환자는 49명(89.1%)이었다. 최대 성장호르몬 값의 log값은 기저 IGF-I 농도와 양의 상관관계를 보였다(r=0.57, P<0.001). 특발성 GHD 환자의 91.7%가 성인기에도 GHD가 지속되어, 성인기 GHD 여부는 소아청소년기 특발성, 기질성 GHD 여부에 따른 차이가 없었다. 동반된 뇌하수체호르몬 결핍 개수가 많을수록(단독 GHD 40%, 1개의 결핍 동반 80%, 2개 이상 동반 95.6%, P=0.002), 기질성 GHD 환자 중에서 병변이 시상하부-뇌하수체를 일차적으로 침범하는 경우(P=0.003)에 성인기에도 GHD가 지속될 가능성이 높았다. 두개 내 방사선 치료를 받은 18명 중에서 15명이 성인기에도 GHD가 지속되었는데, 시상하부-뇌하수체를 침범하는 종양으로 방사선 치료를 받은 환자들 14명은 모두 방사선조사량에 관계없이 성인기에도 GHD가 지속되었다. 동반된 뇌하수체호르몬 결핍이 있는 경우(P=0.005), 소아청소년기 완전 GHD인 경우(P=0.005)에 성인기에도 GHD가 지속되는 비율이 높았다. 결 론 : 소아청소년기에 GHD로 진단 받은 환자들 중에서 동반 뇌하수체호르몬 결핍이 2개 이상이거나, 기저 질환의 병변이 시상하부-뇌하수체를 포함하면 성인기에도 GHD가 지속될 가능성이 높다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제16권10호
• /
• pp.1397-1401
• /
• 2003

The aim of this study was to determine genotypes of four genetic markers and to investigate their association with milk production traits in Brown Swiss cattle imported to Slovakia. The bovine $\kappa$-casein, $\beta$-lactoglobulin, growth hormone and prolactin genotypes of 107 cows were identified by polymerase chain reaction. Effects all four genetic markers on milk, fat, protein and lactose yields and fat, protein and lactose percentage were estimated from a data set of 249 lactations. The frequency of desirable B allele of $\kappa$-casein gene to milk production was 0.46, alleles A of $\beta$-lactoglobulin gene was 0.55, allele and L of growth hormone gene was 0.45 and allele A and B of bovine prolactin gene were 0.61 and 0.39. The results of milk production obtained in our work showed that BB genotypes of $\kappa$-CN gene, AA genotypes of $\beta$-LG gene, LL genotypes of bGH gene were significantly associated with better milk production traits, mainly about the fat content. Association of a bovine prolactin genotypes with milk production were not found.

• Perspectives in Nursing Science
• /
• 제2권1호
• /
• pp.37-47
• /
• 2005

Biobehavioral nursing research is focused on generating knowledge that examines relations among biological, behavioral, and social dimensions of health to improve outcomes. In this paper we review the findings of a biobehavioral nursing study of individuals with fibromyalgia (FM) that was framed from the perspective of an individual human response model, the FM literature, and our previous studies in midlife women. We were particularly interested in the studying the role of 'arousal' secondary to pain or to dysregulated hypothalamic-pituitary-adrenal (HPA) axis hormones during sleep and the impact on symptom expression. Unexpectedly, we did not find evidence of, arousal' or abnormal amounts of HPA axis hormones but we did find reduced amounts of growth hormone (GH) and prolactin (PRL) and of sleep spindle activity, a biomarker of sleep maintenance. We discuss these new findings and how our thinking was re-shaped to better understand the role that disturbed sleep plays in symptom expression in FM. It is argued that disturbed sleep maintenance mechanisms coupled with dysregulated somatotrophic-growth hormone axis and sleep-related PRL render individuals vulnerable to the development of or exacerbations of FM symptoms.

• Animal Bioscience
• /
• 제35권7호
• /
• pp.989-998
• /
• 2022

Objective: This study investigated the effects of intrauterine growth restriction (IUGR) during late pregnancy on the cell growth, proliferation, and differentiation in ovine fetal thymuses. Methods: Eighteen time-mated Mongolian ewes with singleton fetuses were allocated to three groups at d 90 of pregnancy: restricted group 1 (RG1, 0.18 MJ ME/body weight [BW]^0.75/d, n = 6), restricted group 2 (RG2, 0.33 MJ ME/BW^0.75/d, n = 6) and control group (CG, ad libitum, 0.67 MJ ME/BW^0.75/d, n = 6). Fetuses were recovered at slaughter on d 140. Results: The G0/G1 phase cell number in fetal thymus of the RG1 group was increased but the proliferation index and the expression of proliferating cell nuclear antigen (PCNA) were reduced compared with the CG group (p<0.05). Fetuses in the RG1 group exhibited decreased growth hormone receptor (GHR), insulin-like growth factor 2 receptor (IGF-2R), and their mRNA expressions (p<0.05). For the RG2 fetuses, there were no differences in the proliferation index and PCNA expression (p>0.05), but growth hormone (GH) and the mRNA expression of GHR were lower than those of the CG group (p<0.05). The thymic mRNA expressions of cyclin-dependent protein kinases (CDKs including CDK1, CDK2, and CDK4), CCNE, E2-factors (E2F1, E2F2, and E2F5) were reduced in the RG1 and RG2 groups (p<0.05), and decreased mRNA expressions of E2F4, CCNA, CCNB, and CCND were occurred in the RG1 fetuses (p<0.05). The decreased E-cadherin (E-cad) as a marker for epithelial-mesenchymal transition (EMT) was found in the RG1 and RG2 groups (p<0.05), but the OB-cadherin which is a marker for activated fibroblasts was increased in fetal thymus of the RG1 group (p<0.05). Conclusion: These results indicate that weakened GH/IGF signaling system repressed the cell cycle progression in G0/G1 phase in IUGR fetal thymus, but the switch from reduced E-cad to increased OB-cadherin suggests that transdifferentiation process of EMT associated with fibrogenesis was strengthened. The impaired cell growth, retarded proliferation and modified differentiation were responsible for impaired maturation of IUGR fetal thymus.